晚期CKD患者启动RAS抑制剂与CCB的疗效比较:全国性观察性队列研究
本研究基于瑞典肾脏登记2007-2017年数据,比较eGFR<30mL/min/1.73m2的CKD G4-G5患者启动RAS抑制剂或CCB后肾脏替代治疗、死亡及MACE风险。倾向评分加权后,RAS抑制剂组KRT风险显著低于CCB组(aHR 0.79),死亡与MACE风险相似。
要点
- 晚期CKD患者启动RAS抑制剂较CCB显著降低KRT风险(aHR 0.79)。
- 两组全因死亡与MACE风险无显著差异。
- CKD G3阳性对照队列同样显示RAS抑制剂降低KRT风险。
核心结论
- 在晚期CKD患者中,启动RAS抑制剂相比CCB可能带来肾脏获益,且心血管保护相似。
研究设计与样本
- 基于瑞典肾脏登记2007-2017年的观察性研究,纳入2458例RAS抑制剂新用户和2345例CCB新用户,eGFR<30mL/min/1.73m2的CKD G4-G5非透析患者。
- 另设CKD G3(eGFR 30-60mL/min/1.73m2)阳性对照队列。
主要发现
- 中位年龄74岁,女性占38%,中位随访4.1年。
- 倾向评分加权后,RAS抑制剂组KRT风险显著低于CCB组(aHR 0.79,95%CI 0.69-0.89)。
- 全因死亡风险相似(aHR 0.97,95%CI 0.88-1.07),MACE风险相似(aHR 1.00,95%CI 0.88-1.15)。
- CKD G3阳性对照队列中RAS抑制剂同样降低KRT风险(aHR 0.67,95%CI 0.56-0.80)。
临床怎么用
- 对于晚期CKD(G4-G5)非透析患者,启动RAS抑制剂可能延缓肾脏替代治疗,且不增加心血管风险。
局限性
- 存在适应证混杂可能。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
RATIONALE & OBJECTIVE: It is unknown whether initiating renin-angiotensin system (RAS) inhibitor therapy in patients with advanced chronic kidney disease (CKD) is superior to alternative antihypertensive agents such as calcium channel blockers (CCBs). We compared the risks for kidney replacement therapy (KRT), mortality, and major adverse cardiovascular events (MACE) in patients with advanced CKD in routine nephrology practice who were initiating either RAS inhibitor or CCB therapy. STUDY DESIGN: Observational study in the Swedish Renal Registry, 2007 to 2017. SETTINGS & PARTICIPANTS: 2,458 new users of RAS inhibitors and 2,345 CCB users with estimated glomerular filtration rates<30mL/min/1.73m2 (CKD G4-G5 without KRT) who were being followed up by a nephrologist. As a positive control cohort, new users of the same drugs with CKD G3 (estimated glomerular filtration rate, 30-60mL/min/1.73m2) were evaluated. EXPOSURES: RAS inhibitor versus CCB therapy initiation. OUTCOME: Initiation of KRT (maintenance dialysis or transplantation), all-cause mortality, and MACE (composite of cardiovascular death, myocardial infarction, or stroke). ANALYTICAL APPROACH: HRs with 95% CIs were estimated using propensity score-weighted Cox proportional hazards regression adjusting for demographic, clinical, and laboratory covariates. RESULTS: Median age was 74 years, 38% were women, and median follow-up was 4.1 years. After propensity score weighting, there was significantly lower risk for KRT after new use of RAS inhibitors compared with new use of CCBs (adjusted HR, 0.79 [95% CI, 0.69-0.89]) but similar risks for mortality (adjusted HR, 0.97 [95% CI, 0.88-1.07]) and MACE (adjusted HR, 1.00 [95% CI, 0.88-1.15]). Results were consistent across subgroups and in as-treated analyses. The positive control cohort of patients with CKD G3 showed similar KRT risk reduction (adjusted HR, 0.67 [95% CI, 0.56-0.80]) with RAS inhibitor therapy compared with CCBs. LIMITATIONS: Potential confounding by indication. CONCLUSIONS: Our findings provide evidence from real-world clinical practice that initiation of RAS inhibitor therapy compared with CCBs may confer kidney benefits among patients with advanced CKD, with similar cardiovascular protection.
引用
- Fu EL, Clase CM, Evans M, et al. Comparative Effectiveness of Renin-Angiotensin System Inhibitors and Calcium Channel Blockers in Individuals With Advanced CKD: A Nationwide Observational Cohort Study. Am J Kidney Dis. 2020. PMID: 33246024. doi:10.1053/j.ajkd.2020.10.006
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。